#VisualAbstract Menopausal hormone therapy was not associated with risk of cutaneous melanoma

byKathleen Lau

July 22, 2021

in StudyGraphics

#VisualAbstract: Sentinel lymph node-guided neck dissection is noninferior to elective dissections for patients with early oral cavity squamous cell carcinoma

RelatedReports

StudyGraphics

#VisualAbstract: Dermatopathologists have varying perceptions on whether the overdiagnosis of different melanocytic skin lesions is a public health issue

April 28, 2022

StudyGraphics

#VisualAbstract: Ruxolitinib use may be associated with higher incidences of nonmelanoma skin cancers

April 26, 2022

StudyGraphics

#VisualAbstract: Melanoma is projected to remain an important global health concern in 2040, with high incidence rates in fair-skinned populations of European descent

April 14, 2022

StudyGraphics

#VisualAbstract: Solid organ transplant recipients are at an increased risk of developing non-melanoma skin cancers

April 12, 2022

Radiation plus hormone therapy may improve prostate cancer survival

Ipatasertib plus abiraterone significantly improves survival in patients with PTEN-negative prostate cancer compared to abiraterone alone

Dietary variety linked to greater increase in childhood BMI

Automated behavioral intervention for improving workplace diet did not prevent weight gain

#VisualAbstract Addition of daratumumab to standard of care improves minimal residual disease negativity in patients with newly diagnosed, transplant-ineligible multiple myeloma

2 Minute Medicine® is an award winning, physician-run, expert medical media company. Our content is curated, written and edited by practicing health professionals who have clinical and scientific expertise in their field of reporting. Our editorial management team is comprised of highly-trained MD physicians. Join numerous brands, companies, and hospitals who trust our licensed content.

#VisualAbstract Menopausal hormone therapy was not associated with risk of cutaneous melanoma

#VisualAbstract: Dermatopathologists have varying perceptions on whether the overdiagnosis of different melanocytic skin lesions is a public health issue

#VisualAbstract: Ruxolitinib use may be associated with higher incidences of nonmelanoma skin cancers

#VisualAbstract: Melanoma is projected to remain an important global health concern in 2040, with high incidence rates in fair-skinned populations of European descent

#VisualAbstract: Sentinel lymph node-guided neck dissection is noninferior to elective dissections for patients with early oral cavity squamous cell carcinoma

Ipatasertib plus abiraterone significantly improves survival in patients with PTEN-negative prostate cancer compared to abiraterone alone

RelatedReports

#VisualAbstract: Dermatopathologists have varying perceptions on whether the overdiagnosis of different melanocytic skin lesions is a public health issue

#VisualAbstract: Ruxolitinib use may be associated with higher incidences of nonmelanoma skin cancers

#VisualAbstract: Melanoma is projected to remain an important global health concern in 2040, with high incidence rates in fair-skinned populations of European descent

#VisualAbstract: Solid organ transplant recipients are at an increased risk of developing non-melanoma skin cancers

Ipatasertib plus abiraterone significantly improves survival in patients with PTEN-negative prostate cancer compared to abiraterone alone

Automated behavioral intervention for improving workplace diet did not prevent weight gain

#VisualAbstract Addition of daratumumab to standard of care improves minimal residual disease negativity in patients with newly diagnosed, transplant-ineligible multiple myeloma

License Our Award-Winning Physician-Written Medical News and Visual Abstracts

Get 2MM+ Premium Access

Recent Reports

#VisualAbstract Menopausal hormone therapy was not associated with risk of cutaneous melanoma

RELATED REPORTS

#VisualAbstract: Sentinel lymph node-guided neck dissection is noninferior to elective dissections for patients with early oral cavity squamous cell carcinoma

Ipatasertib plus abiraterone significantly improves survival in patients with PTEN-negative prostate cancer compared to abiraterone alone

RelatedReports

License Our Award-Winning Physician-Written Medical News and Visual Abstracts

Get 2MM+ Premium Access

Recent Reports